Russia wants to produce 90% of strategically important medicines

кстате: врёт как 1й канал

оценка импортозамещения.ру Ланцетом:

In 2013, according to one analysis, Russia produced 65% of the drugs on its strategic list and 27% of all the drugs on the market.
According to a Swiss analysis of the industry, in 2009, just 10% of producers were making drugs in accordance with Good Manufacturing Practices (GMP). It's difficult to say how far they've come now but Kavita Rainova, a life-sciences analyst at the industry research company IHS, says that “Last year, for instance, there were discussions over postponing the GMP deadline. The main reason for this discussion was concerns over the ability of many of the companies to set these standards in place by 2014.”
Another obstacle in meeting the production goals relates to the legal system: problems with intellectual property and patent laws, and the lack of clarity regarding laws...
...
But Russia is still an attractive market with a large population and a substantial burden of disease.
...
Hungarian company Gedeon Richter's revenues are down by 50% because of the “war-like” conditions in the region...
...
 it's estimated that around 60% of prescriptions, or around $13 billion worth, are paid for out of pocket and, as a result, compliance is low